Shattuck Labs Stock (NASDAQ:STTK)

Forecast Revenue Ownership Financials Chart

Previous Close

$5.79

52W Range

$0.71 - $8.33

50D Avg

$6.69

200D Avg

$3.72

Market Cap

$295.56M

Avg Vol (3M)

$594.10K

Beta

1.19

Div Yield

-

STTK Company Profile

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

44

IPO Date

Oct 09, 2020

Website

STTK Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/Service	Dec 25	Dec 24
License	$3.40M	$3.40M

Fiscal year ends in Dec 25 | Currency in USD

STTK Financial Summary

	Dec 25	Dec 24	Dec 23
Revenue	$1.00M	$5.72M	$1.66M
Operating Income	$-51.51M	$-80.57M	$-91.96M
Net Income	$-48.81M	$-75.41M	$-87.30M
EBITDA	$-51.51M	$-76.74M	$-87.92M
Basic EPS	$-0.70	$-1.49	$-2.05
Diluted EPS	$-0.70	$-1.49	$-2.05

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts

Q3 23Nov 10, 23 | 8:00 AM

Q4 22Feb 26, 23 | 4:45 PM

Q3 22Nov 12, 22 | 4:30 PM

Peer Comparison

Ticker	Company
IMA	ImageneBio Inc
KLRS	Kalaris Therapeutics Inc
ZNTL	Zentalis Pharmaceuticals, Inc.
ARTV	Artiva Biotherapeutics, Inc.
MGX	Metagenomi, Inc. Common Stock
IFRX	InflaRx N.V.
STRO	Sutro Biopharma, Inc.
CNTX	Context Therapeutics Inc.
CNTB	Connect Biopharma Holdings Limited
OVID	Ovid Therapeutics Inc.